Progression-free survival was improved among patients who received nivolumab and ipilimumab, and toxicity was generally greater among patients who received chemotherapy.
Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval ...
The first of which is peripheral arterial disease (PAD) or low blood flow to the areas. Low blood will decrease kidney function leading to dialysis and will also prevent ulcers from healing leading to ...